Carregant...
A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer
Aim: To report results from the first phase I study of napabucasin plus paclitaxel in Japanese patients with pre-treated unresectable/recurrent gastric cancer. Patients and Methods: Patients received napabucasin (480 mg bid) plus paclitaxel [80 mg/m(2) on days 3, 10 and 17 (cycles 1 and 2) and on da...
Guardat en:
| Publicat a: | In Vivo |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
International Institute of Anticancer Research
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6559899/ https://ncbi.nlm.nih.gov/pubmed/31028219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11561 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|